A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.
“With this new platform, we now have a strategy to convert a solid tumor, at least immunologically, to resemble a hematological tumor, which often has a much higher response rate to immunotherapy treatments,” Jiang said. “If we are able to translate and validate this approach in the clinic, it may enable us to get closer to the maximum level of activity from immunotherapy drugs with cancers that have not traditionally responded well.”
Immunotherapy has high response rates in blood cancers like leukemia and lymphoma, but success has been variable across solid tumors. Scientists have been working to further understand the mechanisms prohibiting a better response. One explanation is that varied expression of immune regulatory molecules on blood cancer versus solid tumor cells impact how they interact with immune cells.
The signaling lymphocytic activation molecule family member 7 (SLAMF7) receptor is critical in activating the body’s immune cells against cancer cells, acting as an “eat me” signal. However, it is found almost exclusively on the surface of blood cancer cells and not in solid tumor cells, making it an attractive target for the researchers’ immune conversion approach.
To promote the expression of SLAMF7 on solid tumor cells, the researchers developed their bispecific tumor-transforming nanoconjugate (BiTN) platform. These nanosystems are designed with one molecule to bind to the surface of targeted tumor cells and a second molecule to activate an immune response.
In this study, the researchers used BiTN with SLAMF7 and a HER2-recognizing antibody to target HER2-positive breast cancer cells. In laboratory models, the nanoconjugate successfully attached SLAMF7 to the breast cancer cells, resulting in phagocytosis, or ingestion, by immune cells. The approach also sensitized the breast cancer cells to treatment with an anti-CD47 antibody, which blocks the “don’t eat me” signal from tumor cells to further increase responses in solid tumors.
According to the authors, one of the most exciting things about this platform is its broad potential applications. The approach would not be specific to one cancer type or one regulatory molecule, rather it has the potential to be a universal strategy for several different solid tumor types. As a proof of concept, the authors also developed BiTN with folate instead of the anti-HER2-antibody to target triple-negative breast cancer with similar results.
“Because these are engineered constructs, this can be used as a plug-and-play approach to incorporate different tumor-targeting agents or immune molecules onto the surface of the nanoparticle,” Kim said. “For patients with solid tumors that have not responded to immunotherapy, we see this as an added advantage to target the part of the tumor that didn’t respond.”
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.
“With this new platform, we now have a strategy to convert a solid tumor, at least immunologically, to resemble a hematological tumor, which often has a much higher response rate to immunotherapy treatments,” Jiang said. “If we are able to translate and validate this approach in the clinic, it may enable us to get closer to the maximum level of activity from immunotherapy drugs with cancers that have not traditionally responded well.”
Immunotherapy has high response rates in blood cancers like leukemia and lymphoma, but success has been variable across solid tumors. Scientists have been working to further understand the mechanisms prohibiting a better response. One explanation is that varied expression of immune regulatory molecules on blood cancer versus solid tumor cells impact how they interact with immune cells.
The signaling lymphocytic activation molecule family member 7 (SLAMF7) receptor is critical in activating the body’s immune cells against cancer cells, acting as an “eat me” signal. However, it is found almost exclusively on the surface of blood cancer cells and not in solid tumor cells, making it an attractive target for the researchers’ immune conversion approach.
To promote the expression of SLAMF7 on solid tumor cells, the researchers developed their bispecific tumor-transforming nanoconjugate (BiTN) platform. These nanosystems are designed with one molecule to bind to the surface of targeted tumor cells and a second molecule to activate an immune response.
In this study, the researchers used BiTN with SLAMF7 and a HER2-recognizing antibody to target HER2-positive breast cancer cells. In laboratory models, the nanoconjugate successfully attached SLAMF7 to the breast cancer cells, resulting in phagocytosis, or ingestion, by immune cells. The approach also sensitized the breast cancer cells to treatment with an anti-CD47 antibody, which blocks the “don’t eat me” signal from tumor cells to further increase responses in solid tumors.
According to the authors, one of the most exciting things about this platform is its broad potential applications. The approach would not be specific to one cancer type or one regulatory molecule, rather it has the potential to be a universal strategy for several different solid tumor types. As a proof of concept, the authors also developed BiTN with folate instead of the anti-HER2-antibody to target triple-negative breast cancer with similar results.
“Because these are engineered constructs, this can be used as a plug-and-play approach to incorporate different tumor-targeting agents or immune molecules onto the surface of the nanoparticle,” Kim said. “For patients with solid tumors that have not responded to immunotherapy, we see this as an added advantage to target the part of the tumor that didn’t respond.”
News
Common Medication Could Save Half a Million Lives Each Year – So Why Isn’t It?
A recent study conducted by scientists at the University of Southern California sheds light on the reasons why children are not receiving an affordable and effective diarrhea treatment. Medical professionals in developing nations are [...]
X Marks the Spot: AI’s Treasure Maps Lead to Early Disease Detection
Medical diagnostics expert, doctor’s assistant, and cartographer are all fair titles for an artificial intelligence model developed by researchers at the Beckman Institute for Advanced Science and Technology. Their new model accurately identifies tumors [...]
Scientists Discover Method To Identify Alzheimer’s Disease Before It Progresses to Dementia
Researchers at Aarhus University have discovered a method to identify Alzheimer’s disease before it progresses to dementia, potentially opening up new avenues for treatment. A groundbreaking study could pave the way for early detection [...]
Startling Discovery: COVID-19 Virus Can Stay in the Body More Than a Year After Infection
The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended, according to new research from UC San Francisco that offers potential [...]
New bioengineered protein design shows promise in fighting COVID-19
In the wake of the COVID-19 pandemic, scientists have been racing to develop effective treatments and preventatives against the virus. A recent scientific breakthrough has emerged from the work of researchers aiming to combat [...]
Sugar-coated gold nanoparticles can quickly eliminate bacterial infections, no antibiotics required
If left to their own devices, bacteria on our teeth or wounded skin can encase themselves in a slimy scaffolding, turning into what is called biofilm. These bacteria wreak havoc on our tissue and, [...]
Liquid Lightning: Nanotechnology Unlocks New Energy
EPFL researchers have discovered that nanoscale devices harnessing the hydroelectric effect can harvest electricity from the evaporation of fluids with higher ion concentrations than purified water, revealing a vast untapped energy potential. Evaporation is a natural [...]
Unmasking the Illusion: AI-Generated Faces Challenge Perceptions
Research shows survey participants duped by AI-generated images nearly 40 percent of the time. If you recently had trouble figuring out if an image of a person is real or generated through artificial intelligence [...]
New Discovery Reveals How Cells Defend Themselves During Stressful Situations
Stress granules play a crucial role in the stress response, arising from the aggregation of non-translating mRNAs and proteins. Although significant knowledge exists about stress granules, the mechanisms behind their mRNA localization remain partially [...]
Scientists use a new type of nanoparticle that can both deliver vaccines and act as an adjuvant
Many vaccines, including vaccines for hepatitis B and whooping cough, consist of fragments of viral or bacterial proteins. These vaccines often include other molecules called adjuvants, which help to boost the immune system's response [...]
Not Science Fiction: How Optical Neural Networks Are Revolutionizing AI
A novel architecture for optical neural networks utilizes wavefront shaping to precisely manipulate the travel of ultrashort pulses through multimode fibers, enabling nonlinear optical computation. Present-day artificial intelligence systems rely on billions of adjustable [...]
Turning skin cells into limb cells sets the stage for regenerative therapy
In a collaborative study, researchers from Kyushu University and Harvard Medical School have identified proteins that can turn or “reprogram” fibroblasts — the most commonly found cells in skin and connective tissue — into [...]
AI reveals prostate cancer is not just one disease
Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer, which could revolutionise how the disease is diagnosed and treated in the future. A Cancer Research UK-funded study, published in Cell Genomics, has revealed [...]
New Study Finds That Persistent COVID-19 Infections Are Surprisingly Common
Recent research conducted by the University of Oxford has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more. The findings have been published in the journal Nature. [...]
Innovative nanosheet method revolutionizes brain imaging for multi-scale and long-term studies
The human brain has billions of neurons. Working together, they enable higher-order brain functions such as cognition and complex behaviors. To study these higher-order brain functions, it is important to understand how neural activity [...]
Scientists Have Discovered a Potential Universal Antivenom
Scientists at Scripps Research identified antibodies that protect against a host of lethal snake venoms. Scripps Research scientists have developed an antibody that can block the effects of lethal toxins in the venoms of [...]